Journal article

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Abstract:: Background Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Folegatti, P. M., Bittaye, M., Flaxman, A., Ramos Lopez, F., Bellamy, D., Mair, C., Makinson, R., Sheridan, J., Boyd, A., Tran, N., Silman, D., Poulton, I., Datoo, M., Marshall, J., Themistocleous, Y., Lawrie, A., Roberts, R., Berrie, E., Lambe, T., … al., E. (2020). Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, 20(7), 816–826.

MLA Style

Folegatti, P. M., et al. “Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-Vectored Vaccine: a Dose-Escalation, Open-Label, Non-Randomised, Uncontrolled, Phase 1 Trial.” Lancet Infectious Diseases, vol. 20, no. 7, Elsevier, 2020, pp. 816–26.

Chicago Style

Folegatti, PM, M Bittaye, A Flaxman, F Ramos Lopez, D Bellamy, C Mair, R Makinson, et al. 2020. “Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-Vectored Vaccine: a Dose-Escalation, Open-Label, Non-Randomised, Uncontrolled, Phase 1 Trial.” Lancet Infectious Diseases 20 (7): 816–26.
Share
Print

Access Document

Files:: supplementary-appendix.pdf

(Preview, Supplementary materials, Version of record, 2.8MB, Terms of use)

Folegatti-et-al-2020-Safety-and-immunogenicity-of-a-candidate-...

(Preview, Version of record, 1.4MB, Terms of use)

Publisher copy:: 10.1016/S1473-3099(20)30160-2

Authors

+ Folegatti, PM More by this author

Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Bittaye, M More by this author

Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Flaxman, A More by this author

Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Ramos Lopez, F More by this author

Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Bellamy, D More by this author

Role:: Author

More authors...

+ Coalition for Epidemic Preparedness Innovations More from this funder

Publisher:: Elsevier
Journal:: Lancet Infectious Diseases More from this journal
Volume:: 20
Issue:: 7
Pages:: 816-826
Publication date:: 2020-04-21
Acceptance date:: 2020-02-28
DOI:: 10.1016/S1473-3099(20)30160-2
EISSN:: 1474-4457
ISSN:: 1473-3099

Language:: English
Keywords:: FFR
Pubs id:: 1096129
Local pid:: pubs:1096129
Deposit date:: 2020-03-24

Terms of use

Copyright holder:: Folegatti et al.
Copyright date:: 2020
Rights statement:: Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP